Navigation Links
Monoclonal Antibody with Xencor's High ADCC Fc Technology Enters Phase 2 Study in B-cell Acute Lymphoblastic Leukemia
Date:4/26/2013

is expressed more broadly and earlier in B-cell development than CD20, the target of the marketed cancer drug Rituxan®. Therefore targeting CD19 could potentially allow for an even broader therapeutic use of MOR208 than marketed anti-CD20 antibodies.

About XmAb® High ADCC Technology
XmAb High ADCC technology can increase the potency of therapeutic antibodies by specifically engaging the body's immune system against target antigen cells. Xencor's proprietary suite of XmAb® Fc variants allows the selective improvement of antibody cytotoxic properties by enhancing antibody-dependent cell cytotoxicity (ADCC), phagocytosis and/or complement activation. Increased antibody potency has the potential to improve antibody efficacy in a variety of therapeutic areas, including oncology, infectious disease and autoimmune disorders.

About Xencor, Inc.

Xencor, Inc. engineers superior biotherapeutics using its proprietary Protein Design Automation® technology platform, and is a leader in the field of antibody engineering to significantly improve antibody half-life, immune-regulatory function and potency. The company is advancing multiple XmAb® antibody drug candidates in the clinic, including XmAb®5871 targeting CD32b and CD19 for autoimmune diseases, and an anti-CD30 candidate XmAb®2513 for the treatment of Hodgkin's lymphoma. Xencor is also advancing a portfolio of biosuperior versions of blockbuster antibody drugs engineered for superior half-life and dosing schedule. Xencor has entered into multiple partnerships with industry leaders such as Amgen, Pfizer, Janssen, MorphoSys, Boehringer Ingelheim, CSL Ltd. and Human Genome Sciences. In these partnerships Xencor is applying its suite of proprietary antibody Fc domains to improve antibody drug candidates for traits such as sustained half-life and/or potency. For more information, please visit www.xencor.com.


'/>"/>
SOURCE Xencor
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology news :

1. Clinical trial for rabies monoclonal antibody
2. New monoclonal antibody developed that can target proteins inside cancer cells
3. Dual action polyclonal antibody may offer more effective, safer protection against osteoporosis
4. Flu antibody’s one-handed grab may boost effort toward universal vaccine, new therapies
5. International Life Sciences Conferences Address Advancements in High-Content Analysis, Sample Preparation, Clinical Trial Supply and Protein and Antibody Engineering
6. Labor der Zukunft -- Tomorrows laboratory technology
7. The future of plant science - a technology perspective
8. The future of plant science a technology perspective
9. Ultracold matter technology from CU and SRI International licensed to Boulders ColdQuanta
10. UF researchers look for ways to make an emerging technology safe for environment
11. Breast cancer risk gene discovery fast tracked by new technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... NEW YORK , Dec. 15, 2014 /PRNewswire-USNewswire/ ... a Good Clinical Practices (GCP) audit to confirm ... Administration (FDA) regulations. This accomplishment enables HITLAB to ... trials utilizing the highest principles for patient safety ... to improve global healthcare access, quality, and delivery ...
(Date:12/11/2014)... 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of ... 2015-2019"  report to their offering. ... advances in technology. With continuous advances in technology, ... the latest standard that meets the needs and ...
(Date:12/10/2014)...  Valencell, a leader in performance biometric data sensor ... from its licensees for highly accurate, clinically validated biometric ... coming from fitness and health sectors, but first responders/military ... is only as useful as the biometric data it ... in long-term mass consumer adoption of wearable products," said ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... GAINESVILLE, Fla. New University of Florida research puts to ... the last glacial period. It turns out it ended up ... The findings have implications for modern-day global warming, said ... of the paper, which is published in this week,s journal ...
... team of researchers based at the Institute of Vertebrate ... professor at Washington University in St. Louis, has discovered ... anthropologists perceptions of the emergence of modern humans in ... published Oct. 25 in the online early edition of ...
... HOUSTON, Oct. 25, 2010 Some unexpected effects ... and reverse blindness have been uncovered by a University ... Donald A. Fox, a professor of vision sciences ... findings in a paper titled "Low-Level Gestational Lead Exposure ...
Cached Biology News:UF research gives clues about carbon dioxide patterns at end of Ice Age 2UF research gives clues about carbon dioxide patterns at end of Ice Age 3Unexpected findings of lead exposure may lead to treating blindness 2Unexpected findings of lead exposure may lead to treating blindness 3
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that ... Cancer Care , a national support services organization for people ... educational programs for people facing lung and ovarian cancers.  The ... their families become aware of options available to help treat ...
... graphite particles 1000 times smaller than the width of a ... boost the efficiencyand profitabilityof solar power plants. Photovoltaic (PV) ... but they,re not necessarily the best solar power solution. "The ... only a fraction of the sunlight that hits them, and ...
... PARIS, April 5, 2011 Cellectis (Alternext: ALCLS), the genome ... signed an agreement with the Caisse des Depots (a French ... in two steps, reserved in equal parts to Cellectis and ... later than January 31, 2012, and is subject to the ...
Cached Biology Technology:Morphotek®, Inc. Receives Beacon Award From CancerCare 2Morphotek®, Inc. Receives Beacon Award From CancerCare 3Nanoparticles improve solar collection efficiency 2Cellectis and Caisse des Depots Sign Agreement on a Project for the Industrial Development of iPS Cells 2Cellectis and Caisse des Depots Sign Agreement on a Project for the Industrial Development of iPS Cells 3